22nd Annual Scientific Sessions:

Shedding Light on Emerging Metabolic Targets in Cardiovascular Diseases

Bordeaux, France 22-25 June 2025

22nd Annual Scientific Sessions:

Shedding Light on Emerging Metabolic Targets in Cardiovascular Diseases

Bordeaux, France 22-25 June 2025

22nd Annual Scientific Sessions:

Shedding Light on Emerging Metabolic Targets in Cardiovascular Diseases

Bordeaux, France 22-25 June 2025

Programme

Programme

  • 11:00-18:30

    Registration [Hotel Lobby]

    10:00-12:00

    SHVM Board Meeting (for board members only)

    13:00-16:30

    Professional Development Session
    sponsored by the Oklahoma State University

    Chairs: Kaitlyn Dennis (Oxford University, UK) and Mark Pepin (Harvard Medical School, USA)

    13:00-13:30

    Christoph Dieterich (Heidelberg University, Germany)
    AI & bioinformatics in cardiovascular research

    13:30-14:00

    Gwang Lee (Ajou University, Republic of Korea)
    AI tool with multiomics for mitochondria research

    14:00-14:45

    AI panel discussion

    Jai Hari Rajendran (Oklahoma State University, USA), Christoph Dieterich (Heidelberg University, Germany), Gwang Lee (Ajou University, Republic of Korea)

    14:45-15:15

    Coffee break

    15:15-15:45

    Meet the Editor

    Gregory Lim (Chief Editor, Nature Reviews Cardiology)

    15:45-16:15

    Tristan Richard (Bordeaux University, France)
    Interest of 1H-NMR for wine analysis

    16:15-17:00

    Round table discussion: career advices from establised investigators and industry sponsors

    Linda R. Peterson, Christine des Rosiers, Mathieu Riuz, Dale Abel, Adam Wende, Adrienne Clements-Egan

    17:00-18:00

    Speed dating Trainees / Established Investigators / Sponsors

    Opening Session

    18:00-18:15

    Welcome from Organisers and SHVM President

    18:15-19:30

    Keynote Lecture

    Chair: Dale Abel (University of California Los Angeles, USA)

    Sihem Boudina (University of Utah, USA)
    The role of autophagy in cardiovascular health and aging

    19:30-23:00

    Informal dinner reception and networking [The Radisson Blu / Lawton restaurant]

  • 8:00-13:00

    Registration [Hotel Lobby]

    6:30-7:30

    Optional Run/Walk (~1-3 mi / ~1.6-5 km) – Quais de Bordeaux (near hotel)

    7:00-8:30

    Breakfast

    8:30-9:30

    Keynote Lecture

    Chairs: Christine des Rosiers (Montreal Heart Institute, Canada) and Pierre Dos Santos (Bordeaux University, France)

    Rong Tian (University of Washington, USA)
    Metabolic mechanisms in pathological cardiac hypertrophy and heart failure

    Session 1 • Targeting Metabolism: Right Ventricular (RV) Dysfunction & Pulmonary hypertension (PHT)

    9:30-10:00

    Christelle Guibert (Bordeaux University, France)
    Implication of reactive oxygen species in PHT

    10:00-10:30

    Stephen Archer (Queen's University, Canada)
    Implication of metabolic reprogramming  and mitochondrial metabolism in RV fibrosis and dysfunction

    10:30-11:00

    Coffee break

    11:00-11:30

    Sung Joon Kim (Seoul National University, Republic of Korea)
    Contractility and metabolic changes in smooth muscle of pulmonary arterial hypertension: potential therapeutic effects of K+ channel activator

    11:00-11:15

    Short talk: Akshay Shekhar (Regeneron Pharmaceuticals, NY, USA)
    CD36 deficiency accelerates the pathogenesis of pulmonary heart disease

    11:15-11:30

    Short talk: Yasutomi Higashikuni (Jichi Medical University, Japan)
    The DEAD-box RNA helicase Ddx41 contributes to adverse cardiac remodeling in response to pressure overload through modulation of RNA metabolism

    12:00-13:00

    Lunch and networking

    13:00-13:30

    MSD Sponsored Lecture
    François Picard (Bordeaux University, France)
    From Bench to bedside in PAH: from BMPR2 pathway to Sotatercept

    Session 2 • Targeting Metabolism in Cardiac Arrhythmias

    Chairs: Florin Despa (Kentucky University, USA) and Kim Mellor (University of Auckland, New Zealand)

    13:30-14:00

    Anuradha Kalyanasundaram (University of North Texas Health Sciences Center, USA)
    Role of fatty infiltrations in cardiac arrhythmias and cardiometabolic diseases

    14:00-14:30

    Jin Li (University of Bern, Switzerland)
    Autoimmune cardiac arrhythmias and calcium homeostasis

    14:30-15:00

    Philippe Pasdois (Bordeaux University, IBGC, France)
    Impact of succinate accumulation in atrial fibrillation

    15:00-15:15

    Short talk: Bernadin Ndongson Dongmo (University of Oslo, Norway)
    Phosphodiesterase 2A overexpression prevents atrial fibrillation and conduction dysfunction independently of diastolic dysfunction in a mouse HFpEF model

    15:15-15:30

    Short talk: Julie Rennison (Cleveland Clinic, OH, USA)
    PPARα signaling is increased but expression of proteins that modulate mitochondrial dynamics are decreased in left atrium of patients in atrial fibrillation

    15:30-16:00

    Coffee break

    16:00-17:00

    Session 3 • The “William C. Stanley” Early Investigator Awards

    Chair: Linda R. Peterson (Washington University, USA)

    Four 15-min presentations from trainee awardees selected from submitted abstracts

    16:00-16:15

    Satoshi Bujo (University of Cambridge, United Kingdom)
    LPLAT7 deficiency impacts cardiomyocyte phospholipid remodeling associated with myocardial dysfunction

    16:15-16:30

    Chloé David (Montreal Heart Institute, Canada)
    The vitamin B paradox: unlocking untapped potential in female heart failure therapy

    16:30-16:45

    Natasha Nambiar (Max Delbruck Centre for Molecular Medicine, Germany)
    The IRE1α arm of the UPR (unfolded protein response) senses lipid stress in cardiac lipotoxicity and engages a novel interactome

    16:45-17:00

    Ríona Devereux (University of Oxford, United Kingdom)
    Identification of the lipid-protein interactome: a novel chemo-proteomic approach to understand cardiometabolic diseases

    17:00-19:00

    Poster Session I / Exhibitions

    19:30-23:30

    Dinner and networking – La Cité du Vin
    (Walk to location starts 19:15 at the hotel reception; La Cité du Vin is roughly 800 m / 10 min away.)

  • 8:00-10:30

    Registration [Hotel Lobby]

    7:00-8:30

    Breakfast

    Session 4 • Targeting Metabolism: From Embryos to Cardiac Organoids

    Chairs: Benjamin Lauzier (Nantes University, France) and Petra Kienesberger (Dalhousie University, Canada)

    8:30-9:00

    Magali Théveniau-Ruissy (Aix-Marseille University, France)
    Impact of maternal obesity on embryonic heart development

    9:00-9:30

    Anna Zoccarato (King's College London, UK)
    Characterization of energy metabolism in human cardiomyocytes derived from induced pluripotent stem cells

    9:30-10:00

    Daan van Aalten (Aarhus University, Denmark)
    Cardiac developmental defects in a mouse model of O-GlcNAc transferase congenital disorder of glycosylation

    10:00-10:15

    Short talk: Louis Berillon (University of Montreal, Canada)
    Endothelial O-GlcNAcylation is crucial for cardiovascular development

    10:15-10:30

    Short talk: Konstantinos Lekkos (University of Oxford, United Kingdom)
    Oxidative phosphorylation is required for cardiomyocyte re-differentiation and long-term fish heart regeneration

    10:30-12:30

    Poster Session II / Exhibitions (with coffee and refreshments)

    12:30-13:30

    Lunch and networking

    Session 5 • Targeting Metabolism in Heart Failure with Preserved Ejection Fraction (HFpEF)

    Chair: Soon-Jun Hong (Korea University, Republic of Korea) and Motohiro Nishid (Kyushu University, Japan)

    13:30-14:00

    Kavita Sharma (John Hopkins School of Medicine, USA)
    Myocardial metabolomics of heart failure with preserved ejection fraction (HFpEF)

    14:00-14:30

    Aldons Lusis (University of California Los Angeles, USA)
    Metabolic perturbances in HFpEF: genetic and microbiota interaction

    14:30-15:00

    Gabriele Schiattarella (Max Delbrück Center, Berlin, Germany)
    Metabolic mechanisms of inter-organ crosstalk in HFpEF

    15:00-15:30

    Coffee break

    15:30-16:00

    Novo Nordisk Sponsored Lecture
    Jean-Sébastien Hulot (Paris University, France)
    GLP1 agonists in heart failure patients

    16:00-16:15

    Short talk: Bellina Mushala (University of Pittsburgh, PA, USA)
    Adropin treatment restores cardiac function and metabolic flexibility in HFpEF

    16:15-16:30

    Short talk: Seema Mital (University of Toronto, Canada)
    Metabolic signature of diastolic dysfunction in cardiomyopathy

    17:00-19:00

    Discover Le Bassin des Lumieres

    19:30-23:00

    Gala Dinner - Le Café Maritime

  • 7:00-8:30

    Breakfast

    8:30-9:30

    "William C. Stanley" Award Lecture

    Chairs: Véronique Lacombe (Oklahoma State University, USA) and Mathias Mericskay (Paris-Saclay University, France)

    Christoph Maack (University Clinic Würzburg, Germany)
    Cost-MetaHeart Lecture - Mechanoenergetic uncoupling during chronic heart failure: novel therapeutic strategies

    Session 6 • Targeting Immunometabolism

    9:30-10:00

    Edward Thorp (Northwestern University, USA)
    Myeloid metabolism in the amplification and resolution of cardiac inflammation

    10:00-10:15

    Short talk: Stefan Gross (University Medicine Greifswald, Germany)
    Exercise exposes dysfunctional immune-metabolic response in heart failure with reduced ejection fraction

    10:15-10:30

    Short talk: Anne Hafstad (UiT-The Arctic University of Norway, Norway)
    MitoLupus: Heart failure development and mitochondrial dynamics in Systemic Lupus Erythematosus (SLE)

    10:30-11:00

    Coffee break

    Session 7 • Targeting Iron Metabolism

    11:00-11:30

    Larimar Therapeutic Sponsored Lecture

    Adrienne Clements-Egan & Christine Des Rosiers
    Specific lipids as potential pharmacodynamic markers for frataxin replacement therapy in Friedreich’s Ataxia

    11:30-12:00

    Lin Liu (Oklahoma State University, USA)
    The role of iron metabolism in pulmonary fibrosis

    12:00-12:30

    Jean-Sébastien Joyal (Montreal University, Canada)
    Microglial heme metabolism improves retinal vascular remodeling and vision in proliferative retinopathy

    12:30-12:45

    FUJIFILM VisualSonics Sponsored Lecture
    Philippe Trochet (FUJIFILM VisualSonics)
    Innovative imaging for cardiovascular diseases — Using VisualSonics High Frequency Ultrasound and Photoacoustics

    12:45-13:00

    Invitation to SHVM 2026

    Japan

    13:00-13:30

    Box Lunch

    Session 8 • Korea BCS and SHVM

    Chairs: Hyoung Kyu Kim (Inje University, Republic of Korea) and Fanny Vaillant (Bordeaux University, France)

    13:30-13:50

    Jin Han (Inje University, Republic of Korea)
    CRBN–TRPC1 axis promotes ER stress and cardiac fibrosis in type 2 diabetes by disrupting calcium homeostasis

    13:50-14:10

    Romain Capoulade (Nantes University, France)
    Role of lipids in aortic valve calcification

    14:10-14:30

    Kyu-Sang Park (Yonsei University Wonju, Republic of Korea)
    The critical role of lactate metabolism in non-shivering thermogenesis

    14:30-14:50

    Jérôme Piquereau (Paris-Saclay University, France)
    Sex-specific benefits of B vitamins supplementation in a murine model of heart failure

    14:50-15:00

    Concluding Remarks

    Organizers and SHVM President

  • When preparing your poster, please remember that its maximum size is A0 (841 x 1189 mm; width x height). Note that the orientation is portrait, not landscape.

    Correct format... poster should be PORTRAIT  poster should NOT be LANDSCAPE Wrong format...

    Poster presenters are required to be available for discussion during their assigned session. The distribution of posters in the two sessions is indicated below.

    Posters in Session I (Monday, 23 June, 17:00-19:00) can be set up as early as Sunday evening or on Monday morning, before the first coffee break. These posters should be taken down on Monday evening. Any posters from this session that are still up by Tuesday at 08:00 will be discarded by the venue personnel so that the posters for Session II can be set up.

    Posters in Session II (Tuesday, 24 June, 10:30-12:30) should be set up on Tuesday morning, in time for the session. These posters should be taken down only on Wednesday morning. Posters left behind after the conclusion of the meeting will be discarded by the venue personnel.

    • Poster Session I • Monday 23 June • 17:00-19:00

      P1.1 · Yong Joo Ahn (Pohang, Republic of Korea)
      Spatial analysis of the composition of human thrombus in acute ischemic stroke

      P1.2 · Michelle Alff (Essen, Germany)
      The dual role of red blood cells in cardioprotection by remote ischemic conditioning: reduction of myocardial infarct size and coronary no-reflow

      P1.3 · Zach Kittle (Stillwater, OK, U.S.A.)
      SARS-COV-2 Infection induces metabolic alterations in the cardiorespiratory system

      P1.4 · Hugues Boel (Montreal, Canada)
      Transcriptomic and lipidomic modulation by EZH2 inhibition in two models of experimental heart failure?

      P1.5 · Anne Cathrine Furuheim Bryn (Tromsø, Norway)
      Trastuzumab and anthracycline therapy alters intermediary metabolism the myocardium

      P1.6 · Gael G.C. Cagnone (Montreal, Canada)
      Metabolic reprogramming of the neovascular niche promotes regenerative angiogenesis in proliferative retinopathy.

      P1.7 · Kaitlyn Dennis (Oxford, United Kingdom)
      ACC and AMPK are post-translationally S-acylated, which is increased by low-flow ischemia

      P1.8 · Matthieu Douard (Pessac, France)
      Basal O-GlcNAcylation is essential to ensure proper electrical activity and calcium handling in rat cardiomyocytes

      P1.9 · Chantal Eickelmann (Essen, Germany)
      More Drp1 in endothelial cells – increased microvascular damage after ischemia/reperfusion injury: a study in isolated perfused rat hearts with endothelium-specific overexpression of Drp1

      P1.10 · Claire Fong-McMaster (Ottawa, Canada)
      Complexome profiling identifies changes in mitochondrial supercomplexes in murine heart failure

      P1.11 · Stefan Gross (Greifswald, Germany)
      Rationale and design of DEEP-HEART - Longitudinal cohort for deep phenotyping of study participants with and without heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF), Greifswald, Germany

      P1.12 · Bastien Guillot (Pessac, France)
      Succinate metabolism remodelling is an actor of the transition from paroxysmal to persistent atrial fibrillation

      P1.13 · Jin Han (Busan, Republic of Korea)
      Unraveling the role of cereblon in cardiac aging: insights from a cardiac-specific deletion model in mice

      P1.14 · Lisa Heather (Oxford, United Kingdom)
      Multiomics-based assessment of 2D/3D human iPSC-cardiomyocyte models of insulin resistance recapitulate diabetic cardiomyopathy

      P1.15 · Lorenz M.W. Holzner (Cambridge, United Kingdom)
      Impacts of early life stress on bioenergetic function in the rat heart – a pilot study

      P1.16 · Xin Hu (Amsterdam, Netherlands)
      Empagliflozin’s protection against in vivo heart failure associates with early SGLT2-independent cardiac changes in transcriptomics and metabolic, but not mechanical, properties of the ex vivo heart

      P1.17 · Yumiko Imai (Daito City, Osaka, Japan)
      Age-related cellular dysregulation in a mouse model of post-intensive care syndrome

      P1.18 · Ezra B. Ketema (Edmonton, Canada)
      Cardiomyocyte SIRT2 deletion impairs glycolysis via hyperacetylation of glycolytic enzymes

      P1.19 · Tobias Klose (Jena, Germany)
      Metabolomic screening identifies novel toxins as potential biomarkers for uremic cardiomyopathy

      P1.20 · Keiji K. Kuba (Fukuoka, Japan)
      CNOT6L deadenylase suppresses cardiac remodeling in heart failure through downregulation of tenascin-C mRNA in fibroblasts

      P1.21 · Wei Liu (Manchester, United Kingdom)
      Blockage of lipotoxicity in cardiomyocytes attenuates heart failure in diabetes

      P1.22 · Kim M Mellor (Auckland, New Zealand)
      Augmented cardiac glycophagy accelerates cardiomyocyte Ca2+ reuptake and remediates diastolic dysfunction in a setting of metabolic stress

      P1.23 · Tien Dung Nguyen (Jena, Germany)
      Glucagon-like Peptide 1 based treatments preserve left ventricular diastolic function - A systematic review and meta-analysis

      P1.24 · Atsuko Okazaki (Tokyo, Japan)
      Deciphering metabolic drivers in pediatric mitochondrial cardiomyopathy: A 20-Year multi-omics approach to therapeutic target discovery

      P1.25 · Gonen Ozsarlak-Sozer (Izmir, Turkey)
      Empagliflozin exerts its effects targeting ER stress in diabetic cardiomyopathy: Is there a role for SIRT1? 

      P1.26 · Mikko Parkkonen (Oulu, Finland)
      MicroRNA editing in primary myocardial fibrosis

      P1.27 · Linda R. Peterson (St. Louis, MO, U.S.A.)
      Gnostic trial: the nanodroplet oxygen delivery (NanO2™) for ST-elevation myocardial infarction

      P1.28 · Annelise Poss (Durham, NC, U.S.A.)
      Targeting succinyl-CoA metabolism: ALA supplementation and ketolysis in pressure-overloaded hearts

      P1.29 · Mario Schubert (Dresden, Germany)
      Advanced mitochondrial development is crucial for modeling myocardial infarction using human induced pluripotent stem cell-derived cardiomyocytes

      P1.30 · Tanin Shafaati (Edmonton, Canada)
      Systemic GIP receptor activation induces diastolic dysfunction in mice with type 2 diabetes

      P1.31 · Nikola Srnic (Oxford, United Kingdom)
      Unsaturated compared to saturated fatty acids improve in vivo human cardiac energetics, systolic, and diastolic function and are associated with upregulated fatty acid oxidation in human cardiomyocytes

      P1.32 · Anna Strano (Dresden, Germany)
      Loss-of-function of leptin receptor impairs metabolism in human cardiomyocytes

      P1.33 · Pamela Swiatlowska (London, United Kingdom)
      Hypertensive pressure mechanosensing triggers transdifferentiation of vascular smooth muscle cells to foam cells

      P1.34 · Eleni Tseliou (Salt Lake City, UT, U.S.A.)
      Cardiac and serum sphingolipid profiles in myocardial recovery after left ventricular assist device support

      P1.35 · Iga M. Walczak (Gdańsk, Poland)
      Metabolic benefits and microvascular improvement in heart failure patients using SGLT2 inhibitors

      P1.36 · Seon Bu Yang (Seoul, Republic of Korea)
      Ubxn4 deficiency aggravates hepatic steatosis in high-fat diet-fed mice

      P1.37 · Aaron Jiashuo Zhang (Oxford, United Kingdom)
      Insulin resistance blunts hypoxia-induced histone lysine methylation in the heart and upregulates expressions of histone lysine demethylases

      P1.38 · Zhenyi Zhao (Orsay, France)
      Phenotypic differences of chronic angiotensin II/phenylephrine infusion to C57BL/6J and C57BL/6N mouse substrains

      P1.39 · Martin Bahls (Greifswald, Germany)
      Exercise exposes dysfunctional immune-metabolic response in heart failure with reduced ejection fraction

      P1.40 · Ríona M. Devereux (Oxford, United Kingdom)
      Identification of the lipid-protein interactome: a novel chemo-proteomic approach to understand cardiometabolic diseases

      P1.41 · Bellina Mushala (Pittsburgh, PA, U.S.A.)
      Adropin treatment restores cardiac function and metabolic flexibility in HFpEF

      P1.42 · Akshay Shekhar (New York, NY, U.S.A.)
      CD36 deficiency accelerates the pathogenesis of pulmonary heart disease

      P1.43 · Chloé David (Montréal, Canada)
      The vitamin B paradox: unlocking untapped potential in female heart failure therapy

      P1.44 · Konstantinos Lekkos (Oxford, United Kingdom)
      Oxidative phosphorylation is required for cardiomyocyte re-differentiation and long-term fish heart regeneration 

      P1.45 · Julie H. Rennison (Cleveland, OH, U.S.A.)
      PPARα signaling is increased but expression of proteins that modulate mitochondrial dynamics are decreased in left atrium of patients in atrial fibrillation

    • Poster Session II • Tuesday, 24 June • 10:30-12:30

      P2.1 · Petra Alanova (Praha, Czechia)
      HIF-1α and mitochondria in cardioprotection induced by adaptation to chronic hypoxia

      P2.2 · Carsten Beets (Stillwater, OK, U.S.A.)
      Exploring the interplay of diabetes and influenza infection: The role of the insulin receptor substrate

      P2.3 · Charlotte Betus (Montréal, Canada)
      Impact of endothelial O-GlcNAcylation in the development and progression of proliferative retinopathy

      P2.4 · Martin Bouaud (Nantes, France)
      O-GlcNAcylation and adaptation to hypoxia during cardiac development

      P2.5 · Nikole Byrne (Graz, Austria)
      SIRT5 improves recovery following myocardial ischemia reperfusion injury by limiting H2O2 production

      P2.6 · David Yin Cai (Hong Kong, China)
      Cardiomyocyte-specific overexpression of GCH1 mitigates HFpEF by reducing oxidative stress via Nrf2 pathway activation

      P2.7 · Christine Des Rosiers (Montreal, Canada)
      Uncovering heart failure (HF) patient subgroups with distinctive clinical and lipid characteristics within and between cohorts using untargeted plasma lipidomics and machine learning

      P2.8 · Gregory Ducker (Salt Lake City, UT, U.S.A.)
      MCT1 is required for the uptake and mitochondrial oxidation of lactate in the myocardium

      P2.9 · Anna A. Faakye (Oklahoma, OK, U.S.A.)
      The pharmacological effect of acetylation in modulating cardiac mitochondrial metabolism

      P2.10 · Ludovic Gomez (Bron, France)
      Limitation of SERCA2a phosphorylation at the heart of cardioprotection

      P2.11 · Giulia Guerra (Turin, Italy)
      Unravelling doxorubicin cardiotoxicity through the lens of metabolism: a multi-omics journey across mitochondrial alterations

      P2.12 · Eva Guilloteau (Nantes, France)
      Is early hyper-O-GlcNAcylation alter placental vascularisation and angiogenesis?

      P2.13 · Kylene M. Harold (Oklahoma City, OK, U.S.A.)
      Impacts of PFKFB2-mediated glycolytic regulation on cardiac electrophysiology and O-GlcNAcylation are fed state-dependent

      P2.14 · Estelle Heyne (Jena, Germany)
      Mitochondrial respiratory capacity in patients with dilated versus ischemic cardiomyopathy – an exploratory analysis

      P2.15 · Yung-Ting Hsiao (Osaka, Japan)
      A brown adipose tissue-derived aging-associated profibrotic protein as a SASP promotes heart fibrosis

      P2.16 · Xin Hu (Amsterdam, Netherlands)
      Exogenous physiological concentrations of lactate and pyruvate play important roles in intrinsic metabolic pathways of the ex vivo mouse heart

      P2.17 · Anu Jose (Saint John, Canada)
      Role of lipid phosphate phosphatase 3 in cardiac lipid and mitochondrial homeostasis

      P2.18 · Hyoung Kyu Kim (Busan, Republic of Korea)
      Cardioprotective Effects of Neopetroside A via GSK-3β Inhibition and Nrf2/NQO1 Activation

      P2.19 · Joanna Konieczny (Tromsø, Norway)
      Fructose-induced liver steatosis model to study the inter-organ crosstalk on the liver-heart axis

      P2.20 · Veronique Lacombe (Stillwater, OK, U.S.A.)
      Protein disulfide isomerase improves cardiac and systemic glucose metabolism during diabetes

      P2.21 · Susan K. Malone (New York, NY, U.S.A.)
      Time-of-day dynamics in cardiometabolic parameters: assessment of cortisol, melatonin, and glucose relationships in adults with prediabetes and short sleep duration

      P2.22 · Miranda Nabben (Maastricht, Netherlands)
      Sex-based differences in cardiomyocyte physiology: investigating cellular and hormonal influences

      P2.23 · Motohiro Nishida (Fukuoka, Japan)
      Supersulfide metabolism in cardiac stress resistance

      P2.24 · Mariola J. Olkowicz (Gdansk, Poland)
      Individuals with heart failure stratified by their left ventricular ejection fraction display distinct lipidomic signatures: insights from the MyoVasc study

      P2.25 · Archee Panwar (Edmonton, Canada)
      Stimulating myocardial glucose oxidation improves cardiac function in diabetic cardiomyopathic mice

      P2.26 · Aleksandra Paterek (Warsaw, Poland)
      Epicardial fat transformation in the vicinity of the failing left ventricle in end-stage heart failure with reduced ejection fraction

      P2.27 · Noemi Polgar (Honolulu, HI, U.S.A.)
      Loss of exocyst function in cardiomyocytes results in heart failure

      P2.28 · José Carlos Rivera (Montreal, Canada)
      Glia-derived lipid metabolites drive pathological angiogenesis in proliferative retinopathy

      P2.29 · Iain Scott (Pittsburgh, PA, U.S.A.)
      Cardiac-specific deletion of GCN5L1 promotes fatty liver disease in HFpEF

      P2.30 · Mahnaz Shariatzadeh (Maastricht, Netherlands)
      Enhancing O-GlcNAcylation as a metabolic intervention in an in vitro model of acute decompensated heart failure

      P2.31 · Klaudia Stawarska (Gdansk, Poland)
      Radiotherapy-induced metabolic and mitochondrial dysregulation of the heart

      P2.32 · Eline Stukkens (Brussels, Belgium)
      A novel sex-dependent role for α-tubulin acetylation on Lys40 in diabetic cardiomyopathy development

      P2.33 · Nolwenn Tessier (Nantes, France)
      O-GlcNAc as a key regulator for survival of babies suffering from congenital heart disease

      P2.34 · Amandine Vergnaud (Nantes, France)
      Unveiling the critical role of O-GlcNAcylation in cardiac development

      P2.35 · Seon Bu Yang (Seoul, Republic of Korea)
      RUNX3 negatively regulates agonists induced cardiac fibroblasts differentiation

      P2.36 · Joo Mi Yi (Busan, Republic of Korea)
      Epigenetic insights into cardiovascular disease: DNA methylation as a potential biomarker for diabetic cardiomyopathy

      P2.37 · Liyan Zhang (Edmonton, Canada)
      R-2-hydroxyglutarate displays anti-proliferation activity in U87 glioblastoma cells by reducing the Warburg effect

      P2.38 · Jie Zheng (Saint Louis, MO, U.S.A.)
      Myocardial oxygen extraction is reduced only in severe fibrotic regions in patients with ischemic heart failure

      P2.39 · Satoshi Bujo (Cambridge, United Kingdom)
      LPLAT7 deficiency impacts cardiomyocyte phospholipid remodeling associated with myocardial dysfunction

      P2.40 · Yasutomi Higashikuni (Shimotsuke-shi, Japan)
      The DEAD-box RNA helicase Ddx41 contributes to adverse cardiac remodeling in response to pressure overload through modulation of RNA metabolism

      P2.41 · Bernadin Ndongson Dongmo (Oslo, Norway)
      Phosphodiesterase 2A overexpression prevents atrial fibrillation and conduction dysfunction independently of diastolic dysfunction in a mouse HFpEF model

      P2.42 · Louis Berillon (Montreal, Canada)
      Endothelial O-GlcNAcylation is crucial for cardiovascular development

      P2.43 · Anne D. Hafstad (Tromsø, Norway)
      MitoLupus: Heart failure development and mitochondrial dynamics in Systemic Lupus Erythematosus (SLE)

      P2.44 · Natasha Nambiar (Berlin, Germany)
      The IRE1α arm of the UPR (unfolded protein response) senses lipid stress in cardiac lipotoxicity and engages a novel interactome